Search

Your search keyword '"Reed, Steven"' showing total 2,224 results
Start Over Author "Reed, Steven"
2,224 results on '"Reed, Steven"'

9. Notes

Author

Reed, Steven R.

Published
1993

10. Cover

Author

Reed, Steven R.

Published
1993

12. Index

Author

Reed, Steven R.

Published
1993

16. Preface

Author

Reed, Steven R.

Published
1993

19. Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Author

Choi, Yu Hwa, Kang, Young Ae, Park, Kwang Joo, Choi, Jae Chol, Cho, Kwan Goo, Ko, Da Yeon, Ahn, Jun Ho, Lee, Boram, Ahn, Eunsol, Woo, Yun Ju, Jung, Kwangsoo, Kim, Nan Yul, Reese, Valerie A., Larsen, Sasha E., Baldwin, Susan L., Reed, Steven G., Coler, Rhea N., Lee, Hyejon, and Cho, Sang-Nae

Published
2023
Full Text
View/download PDF

27. ELISA with recombinant antigen Lb6H validated for the diagnosis of American tegumentary leishmaniasis

Author

Valencia-Portillo, Ruth Tamara, primary, Lindoso, José Angelo, additional, Celeste, Beatriz Julieta, additional, Bittencourt, Amanda Azevedo, additional, de Brito, Maria Edileuza Felinto, additional, Duthie, Malcolm Scott, additional, Guderian, Jeffery, additional, Guerra, Jorge, additional, Oliveira, Ana Lúcia Lyrio, additional, Reed, Steven, additional, Rocha, Mussya Cisotto, additional, Santos, Nicolle Tayná, additional, Silveira, Fernando Tobias, additional, Goto, Hiro, additional, and Sanchez, Maria Carmen Arroyo, additional

Published
2024
Full Text
View/download PDF

28. Versatile tissue‐injectable hydrogels capable of the extended hydrolytic release of bioactive protein therapeutics

Author

Nealy, Eric S., primary, Reed, Steven J., additional, Adelmund, Steven M., additional, Badeau, Barry A., additional, Shadish, Jared A., additional, Girard, Emily J., additional, Brasel, Kenneth, additional, Pakiam, Fiona J., additional, Mhyre, Andrew J., additional, Price, Jason P., additional, Sarkar, Surojit, additional, Kalia, Vandana, additional, DeForest, Cole A., additional, and Olson, James M., additional

Published
2024
Full Text
View/download PDF

29. Reducing Mcl-1 gene dosage induces dopaminergic neuronal loss and motor impairments in Park2 knockout mice.

Author

Ekholm-Reed, Susanna, Baker, Robert, Campos, Alexandre, Stouffer, David, Henze, Martha, Wolf, Dieter, Loring, Jeanne, Thomas, Elizabeth, and Reed, Steven

Subjects
Animals, Behavior, Animal, Cell Count, Disease Models, Animal, Dopaminergic Neurons, Gene Dosage, Gene Knockout Techniques, Mice, Mice, Knockout, Motor Activity, Myeloid Cell Leukemia Sequence 1 Protein, Parkinson Disease, Phenotype, Ubiquitin-Protein Ligases
Abstract

Mutations in the PARK2 gene are associated with early onset Parkinsonism. The Park2 -/- mouse, however, does not exhibit neurodegeneration or other Parkinsons disease (PD) phenotypes. Previously, we discovered that translation of Mcl-1, a pro-survival factor, is upregulated in the Park2 -/- mouse, suggesting a compensatory mechanism during development. Here we generated the Park2 -/- Mcl-1 +/- mouse and show that by reducing Mcl-1 gene dosage by 50%, the Park2 -/- genotype is sensitized, conferring both dopaminergic neuron loss and motor impairments. We propose that this murine model could be a useful tool for dissecting PD etiology and developing treatment strategies against this neurodegenerative disease.

Published
2019

30. Making sense of diabetes medication decisions: a mixed methods cluster randomized trial using a conversation aid intervention

Author

Kunneman, Marleen, Branda, Megan E., Ridgeway, Jennifer L., Tiedje, Kristina, May, Carl R., Linzer, Mark, Inselman, Jonathan, Buffington, Angela L. H., Coffey, Jordan, Boehm, Deborah, Deming, James, Dick, Sara, van Houten, Holly, LeBlanc, Annie, Liesinger, Juliette, Lima, Janet, Nordeen, Joanne, Pencille, Laurie, Poplau, Sara, Reed, Steven, Vannelli, Anna, Yost, Kathleen J., Ziegenfuss, Jeanette Y., Smith, Steven A., Montori, Victor M., and Shah, Nilay D.

Published
2022
Full Text
View/download PDF

32. Correction to: Making sense of diabetes medication decisions: a mixed methods cluster randomized trial using a conversation aid intervention

Author

Kunneman, Marleen, Branda, Megan E., Ridgeway, Jennifer L., Tiedje, Kristina, May, Carl R., Linzer, Mark, Inselman, Jonathan, Buffington, Angela L. H., Coffey, Jordan, Boehm, Deborah, Deming, James, Dick, Sara, van Houten, Holly, LeBlanc, Annie, Liesinger, Juliette, Lima, Janet, Nordeen, Joanne, Pencille, Laurie, Poplau, Sara, Reed, Steven, Vannelli, Anna, Yost, Kathleen J., Ziegenfuss, Jeanette Y., Smith, Steven A., Montori, Victor M., and Shah, Nilay D.

Published
2023
Full Text
View/download PDF

33. Cover

Author

Reed, Steven R.

Published
1986

35. References

Author

Reed, Steven R.

Published
1986

36. Notes

Author

Reed, Steven R.

Published
1986

37. Index

Author

Reed, Steven R.

Published
1986

44. Tables

Author

Reed, Steven R.

Published
1986

48. Adjuvants

Author

Carter, Darrick, Duthie, Malcolm S., Reed, Steven G., Ahmed, Rafi, Series Editor, Akira, Shizuo, Series Editor, Aktories, Klaus, Series Editor, Casadevall, Arturo, Series Editor, Compans, Richard W, Series Editor, Galan, Jorge E, Series Editor, Garcia-Sastre, Adolfo, Series Editor, Malissen, Bernard, Series Editor, Rappuoli, Rino, Series Editor, Hangartner, Lars, editor, and Burton, Dennis R., editor

Published
2020
Full Text
View/download PDF

49. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial

Author

Beckmann, Anna Marie, Hsu, Fan-Chi, Albertson, Sarah, Veldsman, Ashley, Schreuder, Constance, Smit, Erica, Cloete, Yolundi, Ontong, Cynthia, Filander, Elisabeth, Jacobs, Gail, Keyser, Alana, Africa, Hadn, Mulenga, Humphrey, Noble, Julia, Makhethe, Lebohang, Steyn, Marcia, de Kock, Marwou, Quaqua, Nambitha, Lu, Yiwen, Gutschmidt, Andrea, Thienemann, Friedrich, Kahn, Stuart, Mouton, Angelique, Van Rooyen, Elma, Opperman, Fajwa, Swarts, Ann, Van Schalkwyk, Amaryl, Herselman, Yolandi, Hofmeester, Devona, Amsterdam, Julia, Hassanally, Leya, van der Merwe, Linda, Companie, Alessandro, Rossouw, Susan, Jones, Carolyn, Botes, Natasja, van der Riet, Elize, Goliath, Sandra, Kruger, Sandra, Sinandile, Eunice, Day, Tracey A, Penn-Nicholson, Adam, Luabeya, Angelique Kany Kany, Fiore-Gartland, Andrew, Du Plessis, Nelita, Loxton, Andre G, Vergara, Julie, Rolf, Tom A, Reid, Tim D, Toefy, Asma, Shenje, Justin, Geldenhuys, Hendrik, Tameris, Michele, Mabwe, Simbarashe, Bilek, Nicole, Bekker, Linda-Gail, Diacon, Andreas, Walzl, Gerhard, Ashman, Jill, Frevol, Aude, Sagawa, Zachary K, Lindestam Arlehamn, Cecilia, Sette, Alessandro, Reed, Steven G, Coler, Rhea N, Scriba, Thomas J, and Hatherill, Mark

Published
2021
Full Text
View/download PDF

50. A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

Author

Van Hoeven, Neal, Fox, Christopher B, Granger, Brian, Evers, Tara, Joshi, Sharvari W, Nana, Ghislain I, Evans, Sarah C, Lin, Susan, Liang, Hong, Liang, Li, Nakajima, Rie, Felgner, Philip L, Bowen, Richard A, Marlenee, Nicole, Hartwig, Airn, Baldwin, Susan L, Coler, Rhea N, Tomai, Mark, Elvecrog, James, Reed, Steven G, and Carter, Darrick

Subjects
Humans, Influenza Vaccines, Adjuvants, Immunologic, Toll-Like Receptor 7, Toll-Like Receptor 8, Influenza, Human, Influenza A Virus, H5N1 Subtype, Influenza, Infectious Diseases, Pneumonia & Influenza, Immunization, Biodefense, Vaccine Related, Prevention, Emerging Infectious Diseases, 3.4 Vaccines, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Prevention of disease and conditions, and promotion of well-being, Infection, Good Health and Well Being
Abstract

Since 1997, highly pathogenic avian influenza viruses of the H5N1 subtype have been transmitted from avian hosts to humans. The severity of H5N1 infection in humans, as well as the sporadic nature of H5N1 outbreaks, both geographically and temporally, make generation of an effective vaccine a global public health priority. An effective H5N1 vaccine must ultimately provide protection against viruses from diverse clades. Toll-like receptor (TLR) agonist adjuvant formulations have a demonstrated ability to broaden H5N1 vaccine responses in pre-clinical models. However, many of these agonist molecules have proven difficult to develop clinically. Here, we describe comprehensive adjuvant formulation development of the imidazoquinoline TLR-7/8 agonist 3M-052, in combination with H5N1 hemagglutinin (HA) based antigens. We find that 3M-052 in multiple formulations protects both mice and ferrets from lethal H5N1 homologous virus challenge. Furthermore, we conclusively demonstrate the ability of 3M-052 adjuvant formulations to broaden responses to H5N1 HA based antigens, and show that this broadening is functional using a heterologous lethal virus challenge in ferrets. Given the extensive clinical use of imidazoquinoline TLR agonists for other indications, these studies identify multiple adjuvant formulations which may be rapidly advanced into clinical trials in an H5N1 vaccine.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results